Tata Consultancy Services (TCS), the largest exporter of software from India, is now a part of the U.S.-based organization – the Information Technology Industry Council (ITI). The ITI is an organization of IT services, consulting and business solutions providers. The announcement about this development came this week from TCS.

The 60-member strong organization advocates—for its members—international policies that help its members gain access to new markets, promote innovation and leadership, expand e-commerce activities, and undertake sustainability initiatives. All of these activities are geared towards making its members more competitive on an international level.

In his statement on the development, the president and CEO of ITI, Dean Garfield said that the organization was excited about having TCS on board, especially since the company ranks among the most well-recognized players in the IT marketplace. This also makes TCS the first Indian-headquartered company to join the ranks of its contemporaries in the ITI. According to Garfield, TCS’s addition to the ITI comes at an opportune time, when many companies in the industry are making inroads into the Indian market in a bid to engage more with the consumers there.

According to TCS’s president for North America, Europe and UK, Surya Kant, the company stands committed to enabling companies improve their value offerings to customers. He also added that TCS is keen on helping its customers ‘digitally re-imagine’ their service and business offerings across the world.

Kant said that the success of TCS was largely dependent on a highly skilled workforce as well as competitive, open markets, besides developing an environment that fosters the transformation of business.

Harvard Team Develops Blood and Bacteria Repellent Coating Tech for Medical Devices


Scientists at Harvard’s Wyss Institute for Biologically Inspired Engineering have developed blood and bacteria-repellent coating for medical devices. The team said it had recently received a nod of approval from the U.S. Food and Drug Administration. The coating is being called the Tethered-Liquid-Perfluorocarbon (TLP).

The Institute’s founding director Professor Donald E. Ingber, who is also a senior author of the study, said that a TLP coating will cause unwanted materials to slide off the surface. This technology was inspired by a similar coating that was developed by the study’s co-author Joanna Aizenberg in 2011. The coating technology, which she called Slippery Liquid Infused Porous Surfaces (SLIPS), is capable of repelling most solids and liquids. However, TLP differs in that it has been designed specifically for the medical industry. The technology behind SLIPS was inspired by the carnivorous pitcher plant.

The government offered a grant to Ingber for the research and development of TLP – this also indicates that the government considers this technology to have immense potential.

According to Ingber, the military has also showed an interest in the treatment of blood infection without using a coagulant to cleanse bacteria. Backed by the government funding, the team was expected to show results at the earliest. The research solution was developed over a period of two to three years. The solution, according to the team, works “incredibly” in repelling bacteria.

According to the Wyss Institute’s entrepreneur in residence, Eric Devroe, technologies such as antifouling and anticoagulant have a key role to play in the medical devices industry of the future.
The Harvard team now plans to commercialize TLP.

Global Diabetes Devices Drugs Market Will Experience Accelerating Growth, Reaching Revenues of USD 83.0 Billion in 2019



According to a new market report published by U.S. based market research company, Transparency Market Research “Diabetes Devices and Drugs Market (Devices: Diagnostic & Monitoring and Insulin Delivery Devices, Drugs: Insulin Derivatives, GLP-1 and OADs): Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2019” the global diabetes devices and drugs market was valued at USD 54.04 billion in 2012 and is estimated to reach a market worth of USD 83.0 billion in 2019 growing at a CAGR of 5.9% from 2013 to 2019.

Rising prevalence of diabetes is one of the important healthcare concerns on a global level. Insulin is a hormone secreted by pancreas to digest blood sugar. However, in diabetes, it is either not possible for the body to secrete insulin (type-1) or to utilize secreted insulin to metabolize glucose (type-2). The fact (disease conditions), that is, insulin deficiency with the disease is the most important propeller of diabetes devices and drugs market globally. Rising prevalence of diabetes and extensive R&D are the key factors that accentuated the growth of diabetes devices and drugs market. Since no permanent remedy for diabetes has been invented, insulin and drugs therapy, along with proper monitoring and diagnostics have become indispensible part of diabetes patients.

Diabetes devices market is divided into two segments, namely, diabetes diagnostic and monitoring devices and insulin delivery devices. Amongst the diagnostic devices segment, continuous glucose monitoring devices market is expected to grow at a higher growth rate, compared to others. By the end of 2019, test strips market is estimated as the largest in diagnostic and monitoring devices segments. However, market of lancets and analog glucose meters is expected to decline, due to outdated technology. In insulin delivery devices segment, insulin pen is identified as the largest market, followed by syringes. However, by the end of 2019 insulin pumps segment is expected to report highest CAGR.

Diabetes drugs market is segmented as insulin derivatives, oral anti-diabetes drugs and injectable drugs class. Amongst the insulin derivatives segment, long-acting derivatives segment is expected to grow rapidly in the upcoming period. As of 2012, it accounted for the largest market share with 42.77% of the entire market. It is also expected to be the largest segment by the end of 2019. This is followed by rapid-acting insulin market. It is important to highlight that the rest of the segments, such as, premixed, intermediate-acting and short-acting insulin derivatives are expected to decline during the forecast period. While in the oral drugs class segment, the market of SGLT2 inhibitors is expected to grow at an exponential CAGR of 76.8% during forecast period from 2013 to 2019, due to excellent effectiveness in glycemic control and less side-effects. However, traditional drug classes such as sulphonylureas, meglitinides, alpha glucosidase inhibitors and thiazolidinediones are expected to decline during the study period, owing to loss of patents and chronic side-effects. GLP-1 agonists represent injectable drugs class and are also expected to grow at a significant rate during the forecast period. In addition, the report also provides in-depth analysis of pipeline diabetes drugs.

Various products, such as, MK-1293 (Merck & Co., Inc.), LY2605541 (Eli Lilly and Company), IDegLira (Novo Nordisk A/S), Afrezza (MannKind Corporation), Dulaglutide and others are under pipeline studies and expected to enter the market during the forecast period. Hence, on entry of such newer and innovative formulations, the diabetes market is expected to grow steadily during the forecast period.

On the basis of geography, in this report, the diabetes devices and drugs market is segmented into North America, Europe, Asia-Pacific and Rest of the World (RoW). In 2012, the North American region was the largest market in the world, owing to increasing demand of technologically sound devices and sophisticated drugs and rise in diabetic population due to various factors, such as life style and others. However, Asia-Pacific region is assumed as the most promising market during the forecast period from 2013 to 2019. The growth is expected to be driven by factors such as rapidly increasing diabetic population, increased awareness towards self-monitoring and management of diabetes and growing technological penetration in the overall market.

Browse the full Diabetes Devices and Drugs Market report:  

The market is consolidated and highly dominated by selected players operating on a global level. Globally, the market of diabetes devices is dominated by selected number of players, namely; F. Hoffmann La Roche Ltd., LifeScan, Inc. (J&J), Abbott Diabetes Care, and Bayer AG. In addition to this, some other important players that offer an important contribution to the total diabetes devices market include B Braun Melsungen AG and DexCom, Inc. Whereas, Novo Nordisk A/S, Sanofi, Eli Lilly and Company, AstraZeneca plc, Merck, Inc., and Takeda Pharmaceutical Company Limited are the key players having presence in the global diabetes drugs market.

Global Regenerative Medicine (Bone and Joint) Market Will Grow at a Strong Rate Through 2019 by USD 6.5 Billion


According to a new market research report published by Transparency Market Research “Regenerative Medicine (Bone and Joint) Market (By Technology - Stem Cell Therapy, Biomaterial and Tissue Engineering; By Applications - Bone Graft Substitutes, Osteoarticular Diseases, Allogeneic Products, Autogenic Products and Others) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019” the global regenerative medicine (bone and joint) market was valued at USD 2.6 billion in 2012 and is estimated to reach a market worth of USD 6.5 billion in 2019 growing at a CAGR of 12.8% from 2013 to 2019.
Regenerative medicine is considered as an emerging field of medical science that aims to regenerate, repair or replace damaged tissue and organs. U.S. National Institute of Health stated that regenerative medicine is the process of creating functional tissue to repair and replace tissue or organ which has lost their function due to damage, congenital defects, disease and age. Technological advancement in tissue engineering and stem cell therapy is expected to drive the global market for regenerative medicine (bone and joint). Moreover, growing prevalence of bone and joint disorder has also accounted for the market growth of the global regenerative medicine (bone and joint) market. However, ethical issues pertaining to stem cell therapy and fear of disease transmission due to allogeneic bone implantation are considered as market hindering factors during the study period. Companies operating in this market focus on investing in emerging economies of Asia-Pacific such as India, China, Japan and South Korea. These economies represent huge potential for various bone and joint reconstructive products due to rising healthcare expenditure and presence of large patient pool suffering from arthritis disorder (rheumatoid arthritis).
The global market for regenerative medicine is segmented based on technology as stem cell therapy, biomaterials and tissue engineering. In 2012, biomaterials segment accounted for the largest market share in the global regenerative medicine (bone and joint) market owing to favorable reimbursement policies and strong demand of biomaterials in the global market. However, high cost associated with biomaterials is a factor that would restrict the global market demand to some extent during the study period.

In addition, based on applications the global market for regenerative medicine (bone and joint) is segmented as bone graft substitute, osteoarticular diseases, allogeneic bones, autogenic bones and others. In 2012, bone graft substitute segment accounted for the largest market share in the global regenerative medicine bone and joint application market owing to growing demand of bone graft substitute in orthopaedic surgeries. However, post implantation rejection associated with bone graft substitute is considered as a crucial factor that would restrict the global market demand of bone graft substitute.

On the basis of geography, the regenerative medicine (bone and joint) market is segmented as North America, Europe, Asia-Pacific and Rest of the World (RoW). North America accounted for the largest market share for regenerative medicine (bone and joint) globally in 2012 owing to increase in orthopedic reconstructive surgeries and introduction of technologically advanced medical devices and products. According to the American Academy of Orthopedic Surgeons (AAOS), prevalence of Lumbar Spinal Stenosis (LSS) is increasing with rise in elderly population and is estimated that approximately 2.4 million Americans would be affected by LSS by 2021. It has also stated that in 1990 approximately 129,000 Total Knee Arthroplasty (TKA) surgeries were performed in the U.S.

Europe accounted for the second largest share in the global regenerative medicine (bone and joint) market in 2012. Large geriatric population base is one of the important factors driving the growth of regenerative medicine bone and joint application market in this region. Asia-Pacific is expected to grow at the highest CAGR from 2013 to 2019, due to large pool of potential reconstructive surgery patients and strong support from federal government. Additionally, companies are expecting large revenue with sufficient market penetration from Asia-Pacific region and thereby focusing on increasing investments in this region. For instance, in May 2013, Smith & Nephew acquired Sushrut Surgical Pvt. Ltd. an Indian medical technology company. Sushrut Surgicals product portfolio includes trauma implants and instruments, spine and limb salvage products. This acquisition would expand and enhance the product offerings of Smith & Nephew and would also assist in capturing lucrative market share in Asia-Pacific region.

Major market players having presence in the global regenerative medicine (bone and joint) market include DePuy Synthes, Inc. (HEALOS Bone Graft), Medtronic, Inc. (INFUSE Bone Graft) and Zimmer Holdings, Inc. (CopiOs Bone Void Filler), Orthofix, Inc. (Trinity Evolution) and NuVasive, Inc. (Osteocel Plus). 

Browse the full Regenerative Medicine (Bone and Joint) Market report: http://www.transparencymarketresearch.com/regenerative-medicines-market.html

The global regenerative medicine (bone and joint) market is segmented as follows:

Regenerative Medicine (Bone and Joint) Market, by Technology
  • Stem Cell Therapy
  • Biomaterial
  • Tissue Engineering

Regenerative Medicine (Bone and Joint) Market, by Application
  • Bone Graft Substitutes
  • Osteoarticular Diseases
  • Allogeneic Bones
  • Autogenic Bones
  • Others

Regenerative Medicine (Bone and Joint) Market, by Geography
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

Survey Finds Untapped PCI DSS Compliance Opportunities in Public Sector for IT Firms


A recent survey by a firm offering merchant services has found that technology providers stand to benefit considerably from untapped opportunities in PCI DSS compliance in councils.

According to MD of Card Processing Advisory Service (CPRAS), said that as part of this short survey, the company had requested information from 280 councils about their compliance with PCI. CPRAS is a company that helps customers keep tabs on their card payment costs, and to cut them if they are found to be high.

However, only 44 councils responded to the company’s requests, which likely indicate the lack of compliance that exists in this sector. Of the 44 councils that responded, only 11 said they were in compliance. 26 councils acknowledged that they weren’t currently complying with PCI. The remaining seven firms said that they were yet to be certified for PCI compliance, though they were still following the standards.

The company made use of the Freedom of Information Act (FOIA) to obtain information for this survey. From the results, it is evident that IT channel companies could tap this unmet need in the public sector. Opportunities exist in offering assistance or in developing and deploying the right products geared towards compliance.

Hallewell said that the results of non-compliance could be dangerous, as information of individuals could land in the hands of cyber criminals. More importantly, it could affect the critical day-to-day functioning of councils, leading to catastrophic effects. In such a case, councils would also be unable to accept card payments – subjecting them to the payment of fines.

Carbon Black Market for Textile Fibers will expand to reach USD 964.4 Million in 2019



Transparency Market Research has released a new market report titled “Carbon Black Market for Textile Fibers (Polyester, Nylon, Acrylic and Others) for Apparels, Home Textiles and Other End-users – Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2019.” According to the report, the global carbon black market for textile fibers was valued at USD 597.2 million in 2012 and is expected to reach USD 964.4 million by 2019, growing at a CAGR of 7.1% from 2013 to 2019.

Consumption of cotton has been declining globally primarily due to the high cost and low strength of cotton. Furthermore, the increasing demand for arable land for the production of other profitable crops has led to a decrease in the production of cotton. This decline in consumption of cotton has resulted in an increase in demand for synthetic fibers. This is one of the growth drivers for the carbon black market for textile fibers as carbon black is used mainly in the synthetic fibers industry. Other major factors driving demand for carbon black for textile fibers include high growth in the polyester fiber market. Major raw materials employed in the production of carbon black are derivatives of crude oil which have a high carbon content. Volatility in raw material prices and increase in the number of stringent regulations due to several environmental and health hazards associated with carbon black have been restraining the growth of the carbon black for textile fibers market. Increase in research and development activities to develop efficient techniques to produce carbon black from bio-based sources are expected to offer huge growth opportunities in the market.

The carbon black market for textile fibers has been bifurcated into four product segments: polyester, nylon, acrylic and others. Polyester is the largest product segment in the carbon black market for textile fibers and accounted for over 55% share of the global market in 2012. Based on end-users, the carbon black market for textile fibers is bifurcated into three major segments: home textiles, apparels and others. The apparels segment is the most dominant product segment for carbon black market for textile fibers and accounted for around 54% of the global market in 2012. Moreover, the home textiles segment, that includes carpets and sheets, is also a major segment of the carbon black market for textile fibers. Furthermore, the others segment that includes automotive and agricultural textiles is expected to be the fastest growing end-user segment of the carbon black market for textile fibers in the future.

Browse the full Carbon Black Market report:http://www.transparencymarketresearch.com/carbon-black-market.html

Asia Pacific dominated the global demand for carbon black for textile fibers and accounted for 58.2% of the global market in 2012. This trend is anticipated to continue during the forecast period. Major industry participants include Cabot Corporation, Philips Carbon Black Ltd, Birla Carbon and Mitsubishi Chemical Corporation.

New Chinese Military Policy to be a Shot in the Arm for Domestic Chip making Industry


New military guideline recently brought into effect by the Central Military Commission (CMC) in China, will provide a shot in the arm of the country’s chip manufacturing industry. The recent guidelines are aimed enhancing military information management, and will come into force soon.
According to these latest guidelines, the focus will now be on promoting independent IT applications in China, with a view to strengthening military information security. This was reported by Shanghai-based China Business News.

Today, a country’s chip making industry speaks volumes about its competitiveness on the industrial and technological front. This is also the reason why China is laying greater emphasis on its independent IT applications. The country has plans to further strengthen its information security systems, and the new military guidelines are geared towards this.

According to a market research expert, the semiconductor manufacturing sector in China will witness a sea change in the five years ahead. The timing seems to be right, as the chip making industry in China is now reaching a stage of maturity, and will be able to respond more effectively to these guideline changes. Analysts state that chips produced domestically will become more conspicuous in the Chinese market beginning late 2014.

China is under tremendous pressure to emerge as a leader in the cyber security domain, as many other countries are competing for the strategic position. However, producing chips domestically is not an easy option for China, as its semiconductor manufacturing sector is yet to develop fully. A shortage of high-end chips in China is evident, and more capital investments in this sector are required.

Latest Post

Market Research Reports